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co-morbidities. No statistically significant association was observed between CPG 
2009 adherence and co-morbidities. CONCLUSIONS: The study explored the various 
aspects of prescribing pattern of physicians, their adherence to the CPG 2009 and 
the management of DM with other co-morbidities. This study also recognized the 
need for improvement in prescribers’ pattern of prescription and DM management 
with co-morbidities.
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OBJECTIVES: To compare the pivotal clinical endpoints on the prescribing informa-
tion labels of next generation treatments for type 2 diabetes (T2D) and to identify 
the most clinically-relevant antidiabetic outcomes. This multivariate analysis was 
designed to identify the appropriate treatment paradigm for the management of 
patients with T2D, based on symptomatology and relative efficacy. METHODS: 
A multivariate analysis of clinical efficacy endpoints from product information 
labels of 10 recently approved next generation treatments for adult T2D was under-
taken, with 26-week, placebo-controlled endpoint data for utilized all compounds, 
including change from baseline in hemoglobin A1c (%), body weight (kg), fasting 
plasma glucose (mg/dL), post-prandial plasma glucose (mg/dL), and the incidence 
of hypoglycemic events (%). Clinical relevance for this analysis was defined as 1% 
reduction in HbA1c, 5kg reduction in mean body weight from baseline, and an 
incidence of hypoglycemia < 1%. Data with metformin in combination therapy was 
included where available, based on current therapeutic guidelines. RESULTS: The 
multivariate analysis highlighted that no single compound met the predefined 
hypothesis of clinical relevance after 26-weeks of treatment. Canagliflozin 300mg 
/ metformin (-1.06%) and liraglutide (-1.00%) reported the greatest reduction in 
HbA1c. Canagliflozin 300mg / metformin (-4.07kg) and dapaglaflozin 10mg / met-
formin (-2.86kg) had the greatest mean reduction in body weight from baseline. 
Linagliptin 5mg / metformin (0.60%) and dapaglaflozin 10mg / metformin (1.10%) 
had the lowest incidence of hypoglycemia. CONCLUSIONS: Physicians should con-
sider all clinically-relevant outcomes of available T2D therapies with individual 
patient needs before initiating treatment. Clinicians must be aware of the various 
clinical outcomes for available therapies to ensure a safe and effective treatment 
regimen based on the symptomatic profile of individual patients. A triple-goal tar-
geted approach to the management of T2D may reduce healthcare costs and treat-
ment augmentation while improving quality of life for patients.
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OBJECTIVES: Various medications are commonly used to treat pain among indi-
viduals with type 2 diabetes mellitus (T2DM). This study examined the drug uti-
lization trends and factors associated with the use of pain medications among 
patients diagnosed with T2DM. METHODS: Data from the National Ambulatory 
Care Survey (NAMCS) 2006-2010 and the outpatient department component of the 
National Hospital Ambulatory Medical Care Survey (NHAMCS) were used to examine 
diabetes-related ambulatory visits among patients with T2DM. Bivariate chi-square 
analysis and multiple logistic regression were performed to evaluate the factors 
associated with prescribing of pain medications (e.g., anticonvulsants, antidepres-
sants, opioids and some topical agents). SAS survey procedures that adjust for the 
complex sampling procedure of NAMCS and NHAMCS were used. RESULTS: An 
average of 50 million (4.63%) visits was made by patients with T2DM from 2006 to 
2010. The majority of visits were made by females (54.84%), Whites (69.80%) and 
individuals aged 45-64 years (47.66%). Among patients with T2DM, 9.70% were pre-
scribed pain management drugs. The most commonly prescribed pain management 
drugs were anticonvulsants (4.51%), antidepressants (2.80%) and opioids (2.30%). 
Multiple logistic regression analysis showed that females (OR: 1.48; 95% CI: 1.19-
1.82), number of physician visits greater than 1 (OR: 1.39; 95% CI: 1.32-1.46), having 
private insurance (OR: 0.67; 95% CI: 0.49-0.90), and endocrinologist visit (OR: 0.68; 
95% CI: 0.51-0.89) are significant predictors of pain medication use among T2DM 
patients. CONCLUSIONS: Patients with T2DM were prescribed anticonvulsants two 
times more often as compared to opioids for pain management. Dispensed pre-
scriptions for pain medications were related to gender and number of physician 
visits. More frequent pain management related visits from patients over age 65 was 
consistent with the literature. Endocrinologist are less likely to prescribe medication 
for pain management than general medicine specialists.
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OBJECTIVES: To compare time to discontinuation with canagliflozin versus DPP-4 
inhibitors and GLP-1 agonists in patients with T2DM using retrospective claims 
data. METHODS: Patients with T2DM who received a first prescription for a DPP-4 
inhibitor (sitagliptin, saxagliptin, linagliptin), GLP-1 agonist (liraglutide, exenatide, 
exenatide long-acting), or an agent that inhibits SGLT2 (canagliflozin) in 2013 
were extracted from two US claims databases of commercially insured patients 
(Truven, Optum).  The analytical sample included only patients with ≥6 months 
of retrospective data prior to their first paid claim.  Discontinuation was defined 
as an observed refill gap ≥90 days (sensitivity analysis for 30/60 days) between 
BACKGROUND: Previous findings regarding the effect of depression treatment and 
its consequences on health related quality of life (HRQoL) of adults with diabetes 
were inconsistent and targeted certain groups of population. Therefore, there is 
a critical need to perform a study that focuses on a general population with dia-
betes and depression. OBJECTIVES: The primary aim of this study is to examine 
the physical and mental HRQoL associated with depression treatment. METHODS: 
We adopted a longitudinal design using multiple panels (2005-2011) of Medical 
Expenditure Panel Survey to create one year of baseline and one year of follow-
up. We categorized baseline depression treatment into no depression treatment, 
antidepressant use only and psychotherapy with or without antidepressants. We 
used perceived physical and mental health status during the follow-up year as 
measurements of HRQoL. Chi- square tests and multinomial logistic regressions 
were used to examine the association between depression treatment categories 
and HRQoL measures. In the adjusted analysis, we controlled for socio-demographic 
factors, lifestyle risk factors, other chronic conditions, and the baseline HRQoL 
measures. RESULTS: A significant association was observed between depression 
treatment and physical HRQoL measure in both unadjusted and adjusted models. 
Among adults who received psychotherapy (with or without antidepressants) 17.7% 
reported excellent /very good physical HRQoL while only 9.3% of those without 
depression treatment did so. In adjusted analyses, adults who received psycho-
therapy (with or without antidepressants) were more likely to report excellent/ very 
good health compared to those without depression treatment [adjusted OR = 2.32, 
95% CI = 1.01, 5.34]. For mental HRQoL, no significant differences were observed 
between treatment groups in the adjusted model. CONCLUSIONS: Depression treat-
ment, especially psychotherapy (with or without antidepressants) may improve 
physical HRQoL.
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OBJECTIVES: The aim of this study was to determine patient benefit-risk preference 
of insulin treatment, and to examine how preference is predicted by health literacy, 
sociodemographic status and patients own health risk perception. As a secondary 
objective we investigated whether elicited preferences were sensitive to the pres-
entation of benefits as either a surrogate or clinical health outcome METHODS: 
This was a questionnaire based study involving Danish type 2 diabetes patients 
recruited through a diabetes registry. Laboratory- and clinical data on diabetes 
management status was obtained from the registry. The questionnaire included 
a section on diabetes management, health literacy, demographics and a discrete 
choice experiment (DCE). In the DCE, respondents were asked to choose between 
two unlabelled insulin treatments. These were defined by improvements in glucose 
control (HbA1c or long-term sequelae risk reduction), weight control, hypoglycemic 
events (severe/minor) and treatment-related heart attack risk. A Baysian efficient 
design (Ngene v 1.1.1) was used to construct the choice tasks. Logistic regression 
analysis was used to describe the data relationships. Regression coefficients derived 
from this model were used to estimate maximum acceptable risk (MAR) of treatment 
in return of benefit. RESULTS: One thousand and thirty-three patients completed 
the questionnaire. Overall, the avoidance of a minor increase in heart-attack risk 
(3 additional people of 1000) was driving choice of treatment across all versions of 
the DCE. This was followed by avoiding severe hypoglycemic events. We observe 
some differences in preference estimates across the DCE versions indicating that 
patients are sensitive to the presentation of benefit as long-term sequelae risk 
reduction rather than a surrogate measure of health improvement (HbA1c). Detailed 
results on subgroup analysis and predictors of preference are presented at the 
conference. CONCLUSIONS: Risk-aversion of heart attack, although it is a minor 
additional risk, influence patient choice of treatment. Final conclusion is presented 
at the conference.
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OBJECTIVES: To evaluate the prescription pattern, adherence of prescribers with 
Clinical Practice Guideline 2009 and management of diabetes mellitus (DM) with co-
morbidities in a tertiary-care hospital, Pinang General Hospital Malaysia. METHODS: 
Cross-sectional study was performed on a total 51 prescribers and 1020 patients’ 
prescriptions written by the same prescribers (20 prescriptions for each prescriber). 
All 1020 DM patients were suffered with other co-morbidities. All of the prescrip-
tions were divided into two different groups i.e. adherent and non-adherent 
prescriptions. Self-administered research tools were used and demographic charac-
teristics of the patients were determined by descriptive statistics. Data was analyzed 
by using SPSS 21.0. Comparison between adherent and non-adherent groups was 
done by inferential statistics. RESULTS: In all prescriptions, overall good level of 
physician adherence was seen with respect to the recommendations of CPG 2009. A 
statistically significant negative association (Ф= 0.094, p-value= 0.003) was observed 
between DM management and co-morbidities. CPG adherent had shown statisti-
cally weak negative association (Ф= - 0.081, p-value= 0.010) with patients having 
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antidepressants only, $35,099 for psychotherapy only, $33,032 for both and $34,041 
for those receiving no depression treatment. Adjusted linear mixed model analy-
sis revealed that as compared to no depression treatment, depression treatment 
with antidepressants only, psychotherapy only and by both antidepressants and 
psychotherapy reduced total healthcare expenditures by 17%(p-value< 0.001), 
22%(p-value< 0.001) and 28%(p-value< 0.001) respectively. CONCLUSIONS: 
Depression treatment reduced healthcare expenditures suggesting that among 
individuals with T2DM who develop depression, prioritizing treatment for depres-
sion can result in economic benefits.
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OBJECTIVES: Type 2 diabetes mellitus (DM) accounts for over 90% of all diagnosed 
diabetes cases. Hyperglycemia is an important risk factor for diabetic compli-
cations, supporting the use of glucose-lowering agents in the treatment of dia-
betes. Among glucose-lowering agents to treat type 2 DM are oral antidiabetic 
(OAD) agents. The objective of this study was to evaluate the Canadian market 
for OAD agents since 2008, soon after dipeptidyl peptidase (DPP)-4 inhibitors 
were introduced. METHODS: Data on retail prescriptions and on drugstore and 
hospital purchases of OAD agents in Canada were obtained from IMS Brogan. 
Number of prescriptions and purchases (in $Can) were collected for 2008, 2012 
and 2014. RESULTS: Total number of prescriptions for OAD agents in Canada 
amounted to 13.6 million, 20.5 million and 23 million in 2008, 2012, and 2014, 
respectively. Contribution of the two OAD agents mainly prescribed, metformin 
and sulfonylureas, decreased during this period while percentage of prescriptions 
for DPP-4 inhibitors over total OAD agents increased from 0.075% to 6.5% and to 
14.5%, respectively, driven by the increase in prescriptions of sitagliptin, sitaglip-
tin/metformin, saxagliptin, and linagliptin. Total drugstore and hospital purchases 
for OAD agents in Canada reached $394.2 million, $418.7 million and $520.9 million 
in 2008, 2012, and 2014, respectively. Percentage of purchases of DPP-4 inhibitors 
over total OAD agents markedly increased during this period, from 0.5% to 34.1% 
and to 64.1%, respectively. CONCLUSIONS: OAD agents represent a market of 
more than half a billion dollars in Canada; this will likely continue to grow due to 
the increasing occurrence of cases of type 2 DM in the general population. Since 
their introduction in 2008, DPP-4 inhibitor use has grown rapidly so that in 2014, 
they captured approximately one-sixth of prescriptions and, at almost two-thirds 
of purchases, were the market leaders among OAD agents.
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OBJECTIVES: Info-Diabetics’ is becoming an imperative approach in E-health to 
stipulate the diabetic patient care and management. In this study we tried to get an 
overview for application of cellular phone text messaging over adolescent diabetic 
patients (ADPs). The major objective of this study was to test whether adding cellular 
application for patient care compared with control cases would reduce Glycated 
Hemoglobin (HbA1c). METHODS: Eleven ADPs (study cases, n= 11) were selected for 
mobile phone coaching through text messaging, to consultants. ADPs of the control 
site (n= 09) were continued with their standard diabetes health care from consult-
ants. Primarily ADPs were enquired for demographic and social characteristics, 
frequency of cellular phone use, general health information and diagnosis of type 
2 diabetes. Further the level of Hb1Ac, in both the groups, was measured in a regular 
interval of 45 days. After 225 days, percentage of mean improvement in Hb1Ac level 
was compared between cellular users and control cases. RESULTS: More than 3% 
improvement in Hb1Ac was observed among the patients having mobile phone and 
they made regular interaction with consultant. The differences were very small but 
a trend of positive improvement was observed among ADPs using cellular phone’s 
text messaging. CONCLUSIONS: Result indicated that info-diabetic approach may 
contribute to minimize complexities in medical care and the cautious use of cel-
lular phone technology in the form of text messaging would be an asset for self 
care management in ADPs.
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BACKGROUND: In a recent commentary (Basu ERPOR2015), we proposed a solution 
to financing cures in the presence of multiple payers by recommending develop-
ment of a tradable new currency, HealthCoin, which would convert the incremental 
consequences produced by certain well-established cures to a common numeraire 
that can be traded with real dollars in the marketplace among private and pub-
lic payers. OBJECTIVES: To develop the theory behind the provision of a tradable 
HealthCoin for a cure for diabetes between a private payer that provides coverage 
for non-elderly adults, and a public payer (e.g. Medicare) covering the elderly popu-
lation. METHODS: We identify the conditions under which the either payer lacks 
incentive to pay for the cure and where a HealthCoin can overcome these incentives 
problems. We illustrate this theory using empirical estimates for cost-savings and 
life-years gain generated by a cure for diabetes. RESULTS: We find that the precise 
condition required for the valuation of a HealthCoin that would incentivize the 
public payer to offer the HealthCoin as a payment to the private payer, which in turn 
would now have the incentive to purchase the cure, is min{INMBMedicare, PCure} ≥ 
two subsequent prescriptions.   Time to discontinuation was analyzed using 
Kaplan-Meier and Cox proportional hazards regression, including demograph-
ics, treatment background, and diabetes-related complications/comorbidities as 
covariates. RESULTS: 66,206 patients (mean age 52.6 years; 50% male; median/
maximum follow-up, 10.1/19.0 months) were identified in the Truven database. 
After one year, the percentage of patients still on treatment was significantly 
higher with canagliflozin 100 mg (n=7,445; 64.0%) and 300 mg (n=4,486; 65.0%) 
versus DPP-4 inhibitors (30.2% [linagliptin] to 50.1% [sitagliptin]) and GLP-1 ago-
nists (24.3% [exenatide] to 43.0% [liraglutide]) (P <0.0001 for all comparisons).  The 
adjusted hazard ratio (HR) for time to discontinuation for canagliflozin 100 mg 
(reference) and 300 mg (HR=0.92 [0.86;0.99]) was significantly lower versus DPP-4 
inhibitors and GLP-1 agonists: sitagliptin (n=29,426; HR=1.28 [1.22;1.34]); saxagliptin 
(n=1,566; HR=2.01 [1.86;2.16]); linagliptin (n=1,432; HR=2.08 [1.92;2.24]); exenatide 
(n=2,376; HR=2.59 [2.41;2.77]); exenatide long-acting (n=5,922; HR=1.46 [1.40;1.52]); 
liraglutide (n=17,690; HR=1.23 [1.20;1.27]).  Being younger, male, and being on 
monotherapy were associated with higher discontinuation risk.  HRs were stable 
across sensitivity analyses using alternative discontinuation definitions.  Analyses 
from Optum were generally consistent with these results. CONCLUSIONS: These 
analyses indicate that patients who received canagliflozin versus DPP-4 inhibi-
tors or GLP-1 agonists remained on their therapy longer, which may reflect better 
effectiveness and/or tolerability.
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OBJECTIVES: Within the US type 2 diabetes mellitus (T2DM) treatment, following 
metformin failure, is thought to be quite variable given a broad treatment arma-
mentarium. We therefore, sought to determine if newer agent classes or patient 
age influenced prescribing patterns. METHODS: De-identified prescriptions from 
the T2DM analytic platform of the Humedica electronic health records database 
were described, 1/1/2010-6/30/2014. RESULTS: Selection criteria were met by 193,592 
T2DM patients, of whom 71,452 (37%) were ≥ 65 years-old (“elderly”). Of first-line pre-
scriptions, metformin was the most common (59%) followed by SUs (13%), basal (9%) 
and other insulins (9%), DDP4s and DDP4 fixed-dose-combinations (5%), GLP1 (2%), 
TZDs (2%); others ≤ 1%. Metformin first-line monotherapy was prescribed to 140,055 
patients. Of these, 112,387 (80%) remained on monotherapy or discontinued without 
receiving subsequent prescriptions, only 20% progressed to a second-line therapy. 
Top second-line prescriptions were for: metformin+SU (30%), SU monotherapy 
(16%), metformin+DPP4 (9%), DPP4 monotherapy (6%), metformin+basal insulin (4%), 
metformin+GLP1 (4%), DPP4 FDC (4%), metformin+other insulin (3%); others < 3%. 
The elderly received first-line prescriptions for: metformin (49%), SU (18%), insulins 
(basal, 10%; other, 11%), DPP4 FDCs (6%), TZDs (3%), other FDCs (1%), and GLP1s 
(1%). Of the 42,852 elderly receiving metformin monotherapy, 81% either continued 
metformin monotherapy or discontinued without receiving subsequent prescrip-
tions, with 19% progressing to second-line. Top second-line prescriptions among 
the elderly were: metformin+SU (29%), SU monotherapy (22%), metformin+DPP4 
(9%), DPP4 monotherapy (8%), metformin+other insulin (4%), metformin+basal 
insulin (4%), insulin (basal, 3%; other 3%), others < 3%. CONCLUSIONS: First-line 
metformin was most commonly prescribed. Interestingly, despite the availability 
of newer agents classes (e.g., DDD4, GLP1s), most common second-line therapy was 
SU add-on to metformin or monotherapy. Contrary to popular beliefs, we observed 
no age-related differences in prescribing patterns. The outcomes and costs of such 
treatment patterns in the elderly relative to hypoglycemia and its sequelae war-
rants further evaluation.
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OBJECTIVES: To examine whether depression treatment is associated with health-
care expenditures among Medicaid beneficiaries with Type 2 Diabetes Mellitus 
(T2DM) and newly-diagnosed depression. METHODS: A retrospective longitudi-
nal repeated measures cohort design was used.Multi-year (2000-2008) three-state 
Medicaid data were used.The cohort included non-elderly, fee-for-service, continu-
ously enrolled Medicaid beneficiaries with T2DM and newly-diagnosed depression 
(N= 5,295).The depression diagnosis date was the “index-date”; baseline and fol-
low-up periods were defined as 12-months prior and subsequent to the index-date.
Depression treatment received in 120 days after index-date was categorized as, 
treatment with antidepressants only,psychotherapy only,both antidepressants and 
psychotherapy and no treatment.Total healthcare expenditures were calculated for 
each follow-up month.Linear mixed effects regressions on log transformed total 
expenditures were used to examine associations between depression treatment 
and monthly healthcare expenditures after adjusting for random intercept and 
fixed effects of time in months, depression treatment , types of co-existing chronic 
physical conditions (hierarchically classified based on their similarity to T2DM 
pathophysiology and/or management into dominant,concordant only,discordant 
only and both concordant and discordant), gender, age, race/ethnicity, other men-
tal health conditions, Medicaid eligibility due to poverty/medical need/waiver 
(yes/no), baseline healthcare utilization and county of residence characteristics 
such as presence of healthcare infrastructure( e.g.community mental health care 
clinic) and social determinants of health (e.g.county median income). RESULTS: 
Overall,57% had depression treatment (antidepressants only:27.3%, psychotherapy 
only:18.1% and both:11.4%). The average yearly expenditures were $30,590 for 
